These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29903845)

  • 1. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
    Schrieks IC; Nozza A; Stähli BE; Buse JB; Henry RR; Malmberg K; Neal B; Nicholls SJ; Rydén L; Mellbin L; Svensson A; Wedel H; Weichert A; Lincoff AM; Tardif JC; Grobbee DE; Schwartz GG
    Diabetes Care; 2018 Aug; 41(8):1792-1800. PubMed ID: 29903845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
    JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
    Lincoff AM; Tardif JC; Neal B; Nicholls SJ; Rydén L; Schwartz GG; Malmberg K; Buse JB; Henry RR; Wedel H; Weichert A; Cannata R; Grobbee DE
    Am Heart J; 2013 Sep; 166(3):429-34. PubMed ID: 24016490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
    Stähli BE; Nozza A; Schrieks IC; Buse JB; Malmberg K; Mellbin L; Neal B; Nicholls SJ; Rydén L; Svensson A; Wedel H; Weichert A; Lincoff AM; Grobbee DE; Tardif JC; Schwartz GG
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2522-2533. PubMed ID: 29659887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.
    Morici N; Savonitto S; Ponticelli C; Schrieks IC; Nozza A; Cosentino F; Stähli BE; Perrone Filardi P; Schwartz GG; Mellbin L; Lincoff AM; Tardif JC; Grobbee DE
    Am J Med; 2017 Sep; 130(9):1068-1075. PubMed ID: 28344139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
    Bergmark BA; Cannon CP; White WB; Jarolim P; Liu Y; Bonaca MP; Zannad F; Morrow DA
    Diabetes Obes Metab; 2017 Jul; 19(7):962-969. PubMed ID: 28195387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status.
    Jin JL; Cao YX; Liu HH; Zhang HW; Guo YL; Wu NQ; Zhu CG; Xu RX; Gao Y; Sun J; Dong Q; Li JJ
    Cardiovasc Diabetol; 2019 Oct; 18(1):134. PubMed ID: 31610783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.
    van Steen SC; Schrieks IC; Hoekstra JB; Lincoff AM; Tardif JC; Mellbin LG; Rydén L; Grobbee DE; DeVries JH;
    Eur J Prev Cardiol; 2017 May; 24(8):858-866. PubMed ID: 28186441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
    Erdmann E; Califf R; Gerstein HC; Malmberg K; Ruilope L; Schwartz GG; Wedel H; Volz D; Ditmarsch M; Svensson A; Bengus M
    Am Heart J; 2015 Jul; 170(1):117-22. PubMed ID: 26093872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome.
    Klempfner R; Goldenberg I; Fisman EZ; Matetzky S; Amit U; Shemesh J; Tenenbaum A
    Am J Cardiol; 2014 Jan; 113(1):12-6. PubMed ID: 24157192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-hospital free fatty acids levels predict the severity of myocardial ischemia of acute coronary syndrome.
    Ma P; Han L; Lv Z; Chen W; Hu H; Tu J; Zhou X; Liu SM
    BMC Cardiovasc Disord; 2016 Feb; 16():29. PubMed ID: 26830193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
    Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
    Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.
    Savonitto S; Morici N; Nozza A; Cosentino F; Perrone Filardi P; Murena E; Morocutti G; Ferri M; Cavallini C; Eijkemans MJ; Stähli BE; Schrieks IC; Toyama T; Lambers Heerspink HJ; Malmberg K; Schwartz GG; Lincoff AM; Ryden L; Tardif JC; Grobbee DE
    Diab Vasc Dis Res; 2018 Jan; 15(1):14-23. PubMed ID: 29052439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
    Shimada YJ; Cannon CP; Liu Y; Wilson C; Kupfer S; Menon V; Cushman WC; Mehta CR; Bakris GL; Zannad F; White WB;
    Am Heart J; 2016 May; 175():18-27. PubMed ID: 27179720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
    Koomen JV; Heerspink HJL; Schrieks IC; Schwartz GG; Lincoff AM; Nicholls SJ; Svensson A; Wedel H; Weichert A; Grobbee DE; Stevens J
    Diabetes Obes Metab; 2020 Jan; 22(1):30-38. PubMed ID: 31468659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin and future coronary heart disease events among men with type 2 diabetes.
    Schulze MB; Shai I; Rimm EB; Li T; Rifai N; Hu FB
    Diabetes; 2005 Feb; 54(2):534-9. PubMed ID: 15677512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
    Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
    Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.